DGX - Rasio utang marang kapitalisasi buku Quest Corp

Logo grafis Quest Diagnostics (DGX)

The ratio of total liabilities to book capitalization visualizes the financial stability of Quest Diagnostics (DGX), where 0.80 determines the current status of the parameter. The company's extensive laboratory network guarantees predictable cash flow and crisis-resistant demand. Revenues are based on insurance payouts and patient visits. Disciplined management strengthens investor confidence by developing the profitable molecular sector and effectively integrating regional assets.

Quest Diagnostics - Utang-utang marang kapitalisasi buku DGX (periode 04.07.2022 - 27.10.2026)
Barang unggulan Quest

Jim Davis's strategy for expanding the Quest Diagnostics (DGX) network through the acquisition of regional laboratories requires precise control over debt load. Analyzing the company's balance sheet financial leverage, an investor observes the dynamics of the total liabilities-to-equity ratio, where a declining coefficient confirms the business's growing solvency, although it may limit return on equity by reducing the leverage ratio.

Karo sapa Quest Diagnostics saingan

Utang-utang marang kapitalisasi buku A (Agilent Technologies)|illumina.com - Utang-utang marang kapitalisasi buku|Exact Sciences Corporation (EXAS) - Rasio utang marang kapitalisasi buku|RVTY - Rasio utang marang nilai buku|BIO: Utang-utang marang kapitalisasi buku|NNNN (Anbio Corp) - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Sotera Health Company|Rasio utang marang kapitalisasi buku quidel.com (QDEL)|OPKO Health - Utang marang nilai buku|Utang-utang marang nilai buku CDNA (CareDx, Inc)|Rasio utang marang kapitalisasi buku MRVI|Utang-utang marang aset resik Fulgent FLGT|Utang-utang marang kapitalisasi buku LAB (Standard BioTools Inc.)|CTKB: Utang-utang marang aset resik|OraSure - Rasio utang marang kapitalisasi buku|XGN (Exagen) - Utang-utang marang aset resik|MDxHealth Inc. - Rasio utang marang kapitalisasi buku|Utang marang aset resik Lucid Diagnostics, Inc (LUCD)|Utang marang nilai buku PRE|Utang-utang marang kapitalisasi buku imdxinc.com (IMDX)|TRIB: Utang-utang marang kapitalisasi buku|ProPhase Labs Inc - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku AIMD (Ainos Corp)|CoDx (CODX) - Utang-utang marang aset resik|HSCS - Utang marang nilai buku|Utang marang modal buku biomerica.com|CDIO - Utang marang nilai buku|Rasio utang marang aset resik Virax Biolabs Group Limited|Utang-utang marang kapitalisasi buku Bluejay BJDX|Rasio utang marang nilai buku Aspira Women's Health Inc (AWH)|Utang-utang marang kapitalisasi buku AXDX|Utang-utang marang aset resik centogene.com CNTG|Enzo - Utang-utang marang kapitalisasi buku|FRES - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku GENE (gtglabs.com)|ME (23andMe Inc) - Utang marang aset resik|Rasio utang marang kapitalisasi buku Psychemedics (PMD)